Akers Biosciences Inc. (AKER) is a biotechnology company that develops, manufactures, and sells rapid diagnostic screening and testing products. The company was founded in 1989 and is headquartered in Thorofare, New Jersey.
AKER's products are used in a variety of settings, including hospitals, clinics, laboratories, and in the home. The company's tests cover a range of medical conditions, including respiratory infections, gastrointestinal diseases, and other infectious diseases.
However, AKER has faced some financial and legal challenges in recent years. In 2018, the company faced a lawsuit from a former employee who alleged that AKER had made false and misleading statements regarding the effectiveness of its tests. In 2020, the company also faced financial difficulties and was delisted from the Nasdaq stock exchange.
As of February 2023, AKER's stock is traded on the OTC Pink market under the symbol "AKER." However, investors should be aware that OTC Pink stocks are often considered to be more risky and less transparent than stocks listed on major exchanges, and may be subject to additional risks and volatility. As with any investment, investors interested in AKER should carefully consider their investment goals, risk tolerance, and financial situation before making any investment decisions.
|
